Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein
• each of A1, A2, and A3, independently, is CR3 or N, provided that at least one of A1, A2, and A3, independently, is N;
• A4 is CR5 or N;
• L is O, S or NR4,
• R1 is C1-10-alkyl, —OC1-10-alkyl, —NHC1-10-alkyl, —N(C1-10-alkyl)2, C2-10-alkenyl, C2-10-alkynyl or C3-10-cycloalkyl, each of the C1-10-alkyl, —OC1-10-alkyl, —NHC1-10-alkyl, —N(C1-10-alkyl)2, C2-10-alkenyl, C2-10-alkynyl, C3-10-cycloalkyl and C4-10-cycloalkenyl, each of which is optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with 1-5 substituents of R6;
• or R1 is a 3-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, wherein said ring system is optionally substituted independently with 1-5 substituents of R6;
• R2 is H, F, Cl, Br, CF3, NO2, CN, C1-3-alkyl, C1-3-alkoxyl, C1-3-thioalkyl, C1-3-aminoalkyl;
• each R3, independently, is H, F, Cl, Br, CF3, NO2, CN, OH, C1-3-alkyl, C1-3-alkoxyl, C1-3-thioalkyl, C1-3-aminoalkyl or acetyl;
• R4 is H or C1-3-alkyl;
• each R5, independently, is H, F, Br, Cl, I, haloalkyl, NO2, CN, C1-6-alkyl, C1-6-alkoxyl, C1-6-thioalkyl, C1-6-aminoalkyl or di-C1-6-aminoalkyl;
• each R6, independently, is halo, haloalkyl, CN, OH, NO2, NH2, acetyl, oxo, C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, C3-10-cycloalkyl, C4-10-cycloalkenyl, C1-10-alkylamino-, C1-10-dialkylamino-, C1-10-alkoxyl, C1-10-thioalkoxyl, —S(O)2C1-10-alkyl, —C(O)NHC1-10-alkyl, —C(O)NH2, a saturated or partially or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S or —C(O)— saturated or partially or fully unsaturated 3-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, wherein each of the C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, C3-10-cycloalkyl, C4-10-cycloalkenyl, C1-10-alkylamino-, C1-10-dialkylamino-, C1-10-alkoxyl, C1-10-thioalkoxyl and each ring of said ring system and —C(O)-ring system is optionally substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO2, NH2, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl;
• and
• m is 0, 1, 2, 3 or 4.